Published in PLoS One on February 24, 2011
Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res (2013) 1.18
c-Yes regulates cell adhesion at the apical ectoplasmic specialization-blood-testis barrier axis via its effects on protein recruitment and distribution. Am J Physiol Endocrinol Metab (2012) 0.96
Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer. Am J Cancer Res (2012) 0.89
C-Src and c-Yes are two unlikely partners of spermatogenesis and their roles in blood-testis barrier dynamics. Adv Exp Med Biol (2012) 0.88
Differential sensitivity of Src-family kinases to activation by SH3 domain displacement. PLoS One (2014) 0.85
Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas. Oncotarget (2015) 0.79
Phosphotyrosine profiling identifies ephrin receptor A2 as a potential therapeutic target in esophageal squamous-cell carcinoma. Proteomics (2015) 0.77
Activation of Src, Fyn and Yes non-receptor tyrosine kinases in keratinocytes expressing human papillomavirus (HPV) type 16 E7 oncoprotein. Virol J (2013) 0.77
Microarray analyses reveal liver metastasis-related genes in metastatic colorectal cancer cell model. J Cancer Res Clin Oncol (2013) 0.76
LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients. Oncotarget (2016) 0.75
YES oncogenic activity is specified by its SH4 domain and regulates RAS/MAPK signaling in colon carcinoma cells. Am J Cancer Res (2015) 0.75
Spatial cycles mediated by UNC119 solubilisation maintain Src family kinases plasma membrane localisation. Nat Commun (2017) 0.75
Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol (1997) 11.36
The conformational plasticity of protein kinases. Cell (2002) 11.21
The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer (2005) 5.57
Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev (2003) 4.62
Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol (2004) 3.47
The interplay between Src family kinases and receptor tyrosine kinases. Oncogene (2004) 3.36
Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice. Genes Dev (1994) 2.28
Requirement for Src family protein tyrosine kinases in G2 for fibroblast cell division. Science (1995) 1.85
beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res (2003) 1.85
Elevated c-yes tyrosine kinase activity in premalignant lesions of the colon. Gastroenterology (1995) 1.66
Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res (2002) 1.60
Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Oncogene (2006) 1.59
Src continues aging: current and future clinical directions. Clin Cancer Res (2007) 1.50
SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res (2006) 1.42
Nonreceptor tyrosine kinase c-Yes interacts with occludin during tight junction formation in canine kidney epithelial cells. Mol Biol Cell (2002) 1.32
The catalytic activity of the Src family kinases is required to disrupt cadherin-dependent cell-cell contacts. Mol Biol Cell (2000) 1.26
Two distinct pools of Src family tyrosine kinases regulate PDGF-induced DNA synthesis and actin dorsal ruffles. J Cell Sci (2006) 1.11
The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells. Oncogene (2007) 1.11
Transforming potential of Src family kinases is limited by the cholesterol-enriched membrane microdomain. Mol Cell Biol (2009) 1.10
Abl tyrosine kinase regulates a Rac/JNK and a Rac/Nox pathway for DNA synthesis and Myc expression induced by growth factors. J Cell Sci (2005) 1.09
The SRC family protein tyrosine kinase p62yes controls polymeric IgA transcytosis in vivo. Mol Cell (1999) 1.09
Differential activation of pp60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases. Clin Cancer Res (1996) 1.04
Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization. Oncogene (2009) 1.01
c-Yes response to growth factor activation. Growth Factors (2005) 0.91
Two functionally distinct pools of Src kinases for PDGF receptor signalling. Biochem Soc Trans (2005) 0.89
Modulation of cell adhesion molecules in various epithelial cell lines after treatment with PP2. Mol Pharm (2005) 0.80
Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res (2012) 2.04
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res (2008) 1.94
Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest (2002) 1.80
Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res (2008) 1.56
Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol Cell (2008) 1.52
Post-traumatic meningioma: three case reports of this rare condition and a review of the literature. Acta Neurochir (Wien) (2010) 1.50
The interperiosteo-dural concept applied to the perisellar compartment: a microanatomical and electron microscopic study. J Neurosurg (2010) 1.49
A function for phosphoinositide 3-kinase beta lipid products in coupling beta gamma to Ras activation in response to lysophosphatidic acid. J Biol Chem (2002) 1.49
c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. EMBO J (2002) 1.41
Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem (2003) 1.39
S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther (2008) 1.28
Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells. Cancer Res (2009) 1.25
Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood (2003) 1.22
Peroxisome proliferator-activated receptor gamma (PPARgamma ) as a molecular target for the soy phytoestrogen genistein. J Biol Chem (2002) 1.21
Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res (2012) 1.20
NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol (2005) 1.19
Post-translational modification of Bid has differential effects on its susceptibility to cleavage by caspase 8 or caspase 3. J Biol Chem (2003) 1.17
TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS One (2013) 1.13
Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. Biochem J (2008) 1.13
Synthesis, antitumor activity, and mechanism of action of benzo[a]pyrano[3,2-h]acridin-7-one analogues of acronycine. J Med Chem (2006) 1.12
Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol Endocrinol (2008) 1.12
New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol (2003) 1.11
Two distinct pools of Src family tyrosine kinases regulate PDGF-induced DNA synthesis and actin dorsal ruffles. J Cell Sci (2006) 1.11
Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. Blood (2011) 1.11
FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology (2003) 1.11
Abl tyrosine kinase regulates a Rac/JNK and a Rac/Nox pathway for DNA synthesis and Myc expression induced by growth factors. J Cell Sci (2005) 1.09
A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer (2007) 1.08
The adaptor protein Tom1L1 is a negative regulator of Src mitogenic signaling induced by growth factors. Mol Cell Biol (2006) 1.07
Adherens junctions and tight junctions are regulated via different pathways by progastrin in epithelial cells. J Cell Sci (2003) 1.07
Binding kinetics of glucose and allosteric activators to human glucokinase reveal multiple conformational states. Biochemistry (2009) 1.07
Natural ligands of PPARgamma: are prostaglandin J(2) derivatives really playing the part? Cell Signal (2002) 1.04
Update on human alpha1-adrenoceptor subtype signaling and genomic organization. Trends Pharmacol Sci (2004) 1.02
Murine and human autotaxin alpha, beta, and gamma isoforms: gene organization, tissue distribution, and biochemical characterization. J Biol Chem (2008) 1.02
Neuropilin-1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodelling. J Hepatol (2011) 1.02
Cloning of a novel phosphotyrosine binding domain containing molecule, Odin, involved in signaling by receptor tyrosine kinases. Oncogene (2002) 1.00
The active conformation of human glucokinase is not altered by allosteric activators. Acta Crystallogr D Biol Crystallogr (2011) 0.99
Expression of UCP3 in CHO cells does not cause uncoupling, but controls mitochondrial activity in the presence of glucose. Biochem J (2006) 0.98
Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochem Pharmacol (2005) 0.98
Functional invalidation of the autotaxin gene by a single amino acid mutation in mouse is lethal. FEBS Lett (2007) 0.97
Expression and regulation of the nuclear receptor RORalpha in human vascular cells. FEBS Lett (2002) 0.96
Assessment of some tools for the characterization of the human osteoarthritic cartilage proteome. J Biomol Tech (2005) 0.93
Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab (2010) 0.93
The Tom1L1-clathrin heavy chain complex regulates membrane partitioning of the tyrosine kinase Src required for mitogenic and transforming activities. Mol Cell Biol (2007) 0.92
A non-catalytic function of the Src family tyrosine kinases controls prolactin-induced Jak2 signaling. Cell Signal (2010) 0.92
Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management. Pituitary (2013) 0.91
Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3. FEBS Lett (2004) 0.90
Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA). J Neurosci (2011) 0.89
Novel benzopyridothiadiazepines as potential active antitumor agents. J Med Chem (2005) 0.89
Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer. Am J Cancer Res (2012) 0.89
Synthesis and biological study of a new series of 4'-demethylepipodophyllotoxin derivatives. J Med Chem (2005) 0.89
Exploring functional beta-cell heterogeneity in vivo using PSA-NCAM as a specific marker. PLoS One (2009) 0.89
Maxillary surgical seeding of a clival chordoma. Br J Neurosurg (2011) 0.87
Expression of the orphan GPR50 protein in rodent and human dorsomedial hypothalamus, tanycytes and median eminence. J Pineal Res (2010) 0.87
Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors. Biochem Pharmacol (2004) 0.87
The Csk-binding protein PAG regulates PDGF-induced Src mitogenic signaling via GM1. J Cell Biol (2008) 0.86
Syntheses and antiproliferative activities of 7-azarebeccamycin analogues bearing one 7-azaindole moiety. J Med Chem (2003) 0.85
Cyclin E and cyclin A are likely targets of Src for PDGF-induced DNA synthesis in fibroblasts. FEBS Lett (2002) 0.85
Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase. Biochem J (2005) 0.85
Structure-activity relationships of a series of analogues of the RFamide-related peptide 26RFa. J Med Chem (2011) 0.84
Rational design of a low molecular weight, stable, potent, and long-lasting GPR103 aza-β3-pseudopeptide agonist. J Med Chem (2012) 0.84
Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs. Mol Pharmacol (2007) 0.84
Old and new inhibitors of quinone reductase 2. Chem Biol Interact (2010) 0.84
S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol Cancer Ther (2013) 0.84
Appetite-boosting property of pro-melanin-concentrating hormone(131-165) (neuropeptide-glutamic acid-isoleucine) is associated with proteolytic resistance. J Pharmacol Exp Ther (2002) 0.84
Screening of protein kinase inhibitors identifies PKC inhibitors as inhibitors of osteoclastic acid secretion and bone resorption. BMC Musculoskelet Disord (2010) 0.83
Design of novel antitumor DNA alkylating agents: the benzacronycine series. Curr Med Chem Anticancer Agents (2004) 0.83
Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. J Neurosurg (2003) 0.83
Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors. Biochem Pharmacol (2008) 0.83
Molecular pharmacology of the mouse melatonin receptors MT₁ and MT₂. Eur J Pharmacol (2011) 0.83
Synthesis and biological evaluation of aristolactams. Bioorg Med Chem Lett (2002) 0.83
Synthesis and biological activity of sulfonamide derivatives of epipodophyllotoxin. J Med Chem (2004) 0.83
Insights into the redox cycle of human quinone reductase 2. Free Radic Res (2011) 0.83
[Report of seven cases of clear-cell meningioma and a literature review]. Ann Pathol (2010) 0.82
Analysis of SRC oncogenic signaling in colorectal cancer by stable isotope labeling with heavy amino acids in mouse xenografts. Mol Cell Proteomics (2012) 0.82
Molecular pharmacology of adipocyte-secreted autotaxin. Chem Biol Interact (2008) 0.82
Induction of apoptosis in HL-60 leukemia and B16 melanoma cells by the acronycine derivative S23906-1. Biochem Pharmacol (2002) 0.82
Uncoupling protein-3 (UCP3) mRNA expression in reconstituted human muscle after myoblast transplantation in RAG2-/-/gamma c/C5(-) immunodeficient mice. J Biol Chem (2002) 0.82
In vivo characterisation of the human UCP3 gene minimal promoter in mice tibialis anterior muscles. Biochem Biophys Res Commun (2003) 0.82
Synthesis and cytotoxic activity of benzo[c][1,7] and [1,8]phenanthrolines analogues of nitidine and fagaronine. Bioorg Med Chem (2004) 0.82
Enantioselective synthesis of 12-amino alkylidenecyclopentenone prostaglandins. J Org Chem (2002) 0.82
Melatonin MT₁ and MT₂ receptors display different molecular pharmacologies only in the G-protein coupled state. Br J Pharmacol (2014) 0.81
Antiproliferative and iron chelating efficiency of the new bis-8-hydroxyquinoline benzylamine chelator S1 in hepatocyte cultures. Chem Biol Interact (2011) 0.81
Synthesis and biological evaluation of novel naphthocarbazoles as potential anticancer agents. J Med Chem (2005) 0.81
S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. J Pharmacol Exp Ther (2011) 0.81
Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands. J Med Chem (2003) 0.81
Cellular knock-down of quinone reductase 2: a laborious road to successful inhibition by RNA interference. Biochimie (2007) 0.81
New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors. Int J Mol Sci (2013) 0.81